Clinical trials: Basal Cell Cancer
Basal Cell Nevus Syndrome
Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)
This is a multicenter, open label extension study evaluating the safety of Patidegib Topical Gel, 2%, applied topically twice daily to the face of adult subjects with Gorlin syndrome.
- Trial name
- NCT04308395
- Testing
- Patidegib Topical Gel, 2%
- Where
- 37 sites in United States, Belgium and 7 more
- Volunteers
- 108 people
- Sponsor
- Sol-Gel Technologies, Ltd.
Basal Cell Carcinoma
A Study of IO103 in Montanide Adjuvant for Basal Cell Carcinoma
A single center, open-label, phase IIa, single arm, window of opportunity trial with IO103 and Montanide adjuvant in patients with surgically resectable BCC.
- Trial name
- NCT03714529
- Testing
- PD-L1
- Where
- Denmark
- Volunteers
- 10 people
- Sponsor
- Herlev and Gentofte Hospital
Nodular Basal Cell Carcinoma
Surgery Versus Combined Treatment With Curettage and Imiquimod for Nodular Basal Cell Carcinoma
Basal cell carcinoma (BCC) is a slow-growing, locally invasive malignant epidermal skin tumour. It is the most common malignant disease in Caucasians, representing approximately 80% of all cases of skin cancer and is therefore an…
- Trial name
- SCIN (NCT02242929)
- Testing
- Imiquimod 5% cream with prior curettage, Standard surgical excision
- Where
- Netherlands
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Basal Cell Carcinoma of Skin, Optical Coherence Tomography (OCT)
Real-world Evaluation of the Implementation of LC-OCT in Daily Clinical Practice
Basal cell carcinoma (BCC) is the most common skin cancer in the Netherlands, with incidence rates continuing to rise. The current diagnostic standard combines clinical evaluation and dermoscopy, while biopsy followed by…
- Conditions
- Basal Cell Carcinoma of Skin, Optical Coherence Tomography (OCT), Neoplasms, Neoplasms, Basal Cell
- Trial name
- RELI (NCT07501780)
- Where
- Netherlands
- Volunteers
- 297 people
- Sponsor
- Maastricht University Medical Center
Bladder Cancer, Breast Cancer
Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or…
- Conditions
- Bladder Cancer, Breast Cancer, Carcinoma of Unknown Primary, Esophageal Cancer
- Trial name
- NCT00014456
- Testing
- filgrastim, docetaxel, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Basal Cell Carcinoma
cOCT Versus LC-OCT for Diagnosing Basal Cell Carcinoma: a Diagnostic Cohort Study
Basal cell carcinoma (BCC) is the most common form of cancer among the Caucasian population. Equivocal BCC lesions are usually diagnosed by means of a punch biopsy, but since the last few decades, non-invasive imaging techniques…
- Trial name
- NCT06024629
- Testing
- cOCT and LC-OCT
- Where
- Netherlands
- Volunteers
- 197 people
- Sponsor
- Maastricht University Medical Center
Stage IV Melanoma, Advanced Lung Cancer
Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer
The purpose of this study is to refine and pilot test educational material developed to educate and support patients receiving immunotherapy for advanced cancer.
- Conditions
- Stage IV Melanoma, Advanced Lung Cancer, Stage IV Non-Small Cell Lung Cancer, Unresectable Non-Small Cell Lung Carcinoma
- Trial name
- UPLIFT (NCT04670445)
- Testing
- Educational Video and QPL List, Usual Care
- Where
- United States
- Volunteers
- 199 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Non-melanomatous Skin Cancer
Imiquimod Cream in Treating Patients With Basal Cell Skin Cancer
RATIONALE: Biological therapies, such as imiquimod cream, work in different ways to stimulate the immune system and stop tumor cells from growing.
- Trial name
- NCT00079300
- Testing
- imiquimod, conventional surgery
- Where
- United States
- Sponsor
- National Naval Medical Center
Non-melanomatous Skin Cancer
Topical Imiquimod Compared With Surgery in Treating Patients With Basal Cell Skin Cancer
RATIONALE: Biological therapies such as imiquimod use different ways to stimulate the immune system and stop cancer cells from growing.
- Trial name
- NCT00066872
- Testing
- imiquimod, conventional surgery
- Where
- 3 sites in United Kingdom
- Volunteers
- 500 people
- Sponsor
- Queen's Medical Center
Melanoma (Skin), Non-melanomatous Skin Cancer
Isotretinoin in Preventing Skin Cancer
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Isotretinoin may be effective in preventing the development or recurrence of skin cancer.
- Trial name
- NCT00025012
- Testing
- isotretinoin
- Where
- United States
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Non-melanomatous Skin Cancer
Topical Aminolevulinic Acid in Patients With Nonmelanoma Skin Cancer
RATIONALE: Studying samples of tumor tissue in the laboratory from patients with nonmelanoma skin cancer that has been treated with topical aminolevulinic acid may help doctors predict how patients will respond to photodynamic…
- Trial name
- NCT00663910
- Testing
- Aminolevulinic Acid, biopsy, diagnostic imaging technique
- Volunteers
- 18 people
- Sponsor
- The Cleveland Clinic
Basal Cell Carcinoma of the Skin, Eccrine Carcinoma of the Skin
Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma
This pilot clinical trial studies isolated limb perfusion with melphalan in treating patients with stage IIIB-IV melanoma or sarcoma.
- Conditions
- Basal Cell Carcinoma of the Skin, Eccrine Carcinoma of the Skin, Recurrent Adult Soft Tissue Sarcoma, Recurrent Melanoma
- Trial name
- NCT02507076
- Testing
- isolated limb perfusion, melphalan, quality-of-life assessment
- Where
- United States
- Sponsor
- Albert Einstein College of Medicine
Basal Cell Carcinoma
PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Participants With Primary Nodular Basal Call Carcinoma
Photodynamic therapy (PDT) was the selective destruction of abnormal cells through light activation of a photosensitiser in the presence of oxygen. These cells accumulated more photosensitiser than normal cells.
- Trial name
- NCT00472043
- Testing
- PDT with Metvix 160 mg/g cream
- Where
- 7 sites in Australia
- Volunteers
- 66 people
- Sponsor
- Galderma R&D
Basal Cell Carcinoma
AI-Based Risk Classification and Histopathological Subtype Prediction of Basal Cell Carcinoma Using Dermoscopic Images
This retrospective observational study aims to develop and evaluate a convolutional neural network (CNN)-based artificial intelligence model for risk classification and histopathological subtype prediction of basal cell carcinoma…
- Trial name
- BCC-AI (NCT07677124)
- Where
- Turkey (Türkiye)
- Volunteers
- 2,500 people
- Sponsor
- Istanbul Training and Research Hospital
Locally Advanced Basal Cell Carcinoma
Tailored Sonidegib Schedule After Complete Response in BCC
Adult patients with locally advanced BCC, not amenable to surgical treatment and who obtained a complete response (CR) to Hedgehog inhibitors are administered a tailored schedule of the study drug.
- Trial name
- SONIBEC (NCT04806646)
- Testing
- Sonidegib
- Where
- Italy
- Volunteers
- 21 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Erysipelas, Impetigo
Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo
The purpose of this study is to demonstrate the validity and utility of a tele-dermatology system in the midterm periodic screening of non-widespread skin lesions of recent onset or for which a specialized early classification is…
- Conditions
- Erysipelas, Impetigo, Herpes Zoster, Molluscum Contagiosum
- Trial name
- NCT02902822
- Testing
- Screening, Tele-dermatology
- Where
- Italy
- Volunteers
- 461 people
- Sponsor
- Centro Studi Gised
Treatment for Basal Cell Carcinomas (BCCs) in Gorlin Syndrome Patients
A Trial to Evaluate the Safety, Local Tolerability, Pharmacokinetics and Pharmacodynamics of LDE225 on Skin Basal Cell Carcinomas in Gorlin Syndrome Patients
Part I was a double-blind, randomized, vehicle-controlled Proof of Concept (PoC) study to evaluate the safety, local tolerability, pharmacokinetics and pharmacodynamics of multiple topical administrations of LDE225 (a specific…
- Trial name
- NCT00961896
- Testing
- Vehicle, LDE225 0.25%, LDE225 0.75%
- Where
- 3 sites in Austria, Switzerland
- Volunteers
- 18 people
- Sponsor
- Novartis Pharmaceuticals
Parkinson's Disease, Malignant Melanoma
A Survey Study to See if Patients Diagnosed With Parkinson's Disease Have Higher Incidence of Melanoma
Patients with Parkinson's disease will be seen by a dermatologist who will biopsy any suspicious skin lesions.
- Trial name
- NCT00203008
- Volunteers
- 2,106 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Melanoma (Skin), Melanoma in Situ
Research of Pathological Imaging Diagnosis of Ocular Tumors Based on New Artificial Intelligence Algorithm
The purpose of this study is to establish a standardized process for obtaining digital pathological image information of ocular tumors; use modern pathological techniques to obtain the co-expression information of multiple…
- Conditions
- Melanoma (Skin), Melanoma in Situ, Nevus Eye, Sebaceous Gland Carcinoma of the Eyelid
- Trial name
- NCT04695015
- Volunteers
- 100 people
- Sponsor
- Peking University
Basal Cell Carcinoma
Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)
This 22 week study will assess the efficacy, safety, and tolerability of LDE225 versus vehicle when applied topically to basal cell carcinoma (BCC) in patients with NBCCS. Patients will treat multiple BCCs for up to 12 weeks.
- Trial name
- NCT03070691
- Testing
- LDE225B, Vehicle
- Where
- 35 sites in Belgium, Canada and 8 more
- Sponsor
- Novartis Pharmaceuticals